Background and Purpose-Wake-up ischemic stroke (WUIS) patients are not eligible for thrombolysis; the a priori hypothesis was that thrombolysis of selected WUIS patients who meet clinical and imaging criteria for treatment is associated with better outcomes. Methods-The sample consisted of consecutive WUIS patients who fulfilled predefined criteria: (1) were last seen normal >4.5 hours and <12 hours before presentation; (2) National Institute of Health Stroke Scale score ≥5; (3) No or early ischemic changes <1/3 middle cerebral artery territory on computed tomography imaging; (4) No absolute contraindications to thrombolysis. The primary outcome measure was the modified Rankin Scale of 0 to 2 at 90 days.
P
eople who wake up with symptoms of stroke account for 8% to 27% of ischemic stroke patients but are not thrombolysed because of unknown onset time.
1,2 These patients have poorer natural outcomes both with respect to discharge destination 3 and functional outcomes 1, 4 compared to patients with known time of stroke. Studies show that many patients with wake-up ischemic stroke (WUIS) have clinical and radiological characteristics similar to patients with a known time of stroke onset who receive thrombolytic treatments. 1, 2, [5] [6] [7] The a priori hypothesis prior to data collection for this study was that thrombolysis of WUIS patients with clinical and imaging findings of early ischemia will be associated with better outcomes at 90 days.
Methods
The study was undertaken at a tertiary stroke center offering thrombolysis with informed consent to WUIS patients with moderately severe persistent neurological deficits who meet the clinical and noncontrast computed tomography (NCCT) imaging eligibility criteria for thrombolysis and would have been treated if presenting within 4.5 hours of stroke onset. Patients were assessed on arrival by stroke fellows using the National Institute of Health Stroke Scale (NIHSS) 8 and NCCT brain images were assessed for early ischemic changes using the Alberta Stroke Program Early Computed Tomography Score. 9 Early ischemic changes and hyperdense cerebral arteries were further defined using reconstructed thin slices measuring 1.25 mm. 10 Computed tomography perfusion (CTP) imaging was not an obligatory requirement for decision to thrombolyse, but was undertaken immediately after NCCT in 64/122 (52%) of WUIS patients at the request of the treating physician. There were no prespecified mismatch-based criteria for thrombolysis, which remained a clinical decision. Standard dosage schedules for thrombolysis were followed. Patients were managed on the stroke intensive care unit and a follow-up computed tomography (CT) scan was performed at 24 hours. This off-label use of recombinant tissue plasminogen activator (rtPA) with consent is approved by the Novel Procedures and Therapeutics Committee of the Institution.
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Subjects were selected by consecutive sampling of a prospective register between January 2009 and December 2010. Data on all patients are collected prospectively on this register and include details of demography, vascular risk profile, clinical details at presentation, including baseline observations, NIHSS scores, imaging, treatment, and treatment times. The predefined inclusion criteria for thrombolysed and nonthrombolysed WUIS patients were: (1) were last seen normal <12 hours or >4.5 hours after symptom onset; (2) no neurological deficits when last seen awake and witnessed persistent deficits on awakening; (3) emergency presentation to hospital; (4) NIHSS score ≥5 on initial assessment; (5) no or early ischemic changes of <1/3 middle cerebral artery territory on baseline CT scan; and (6) no absolute contraindications to rtPA use. WUIS patients were excluded from the analysis, if NCCT showed extensive (>1/3 middle cerebral artery territory or multiple territories involved) or established (defined lesion margins on NCCT) infarction. The data extracted are shown in Table 1 and were verified against source data from medical records and CT images for completeness and accuracy. Stroke pathogenesis was categorized after review of medical records and investigations by 2 independent investigators.
The primary outcome measure was the dichotomized modified Rankin Scale (mRS), defined as excellent (mRS 0-1) or good (mRS 0-2), and assessed at 90 days. This and mortality were assessed by trained and certified assessors, unaware of initial clinical management during a clinic visit or by telephone. 11 Intracranial hemorrhages on follow-up CT scans were classified according to European Cooperative Acute Stroke Study (ECASS) II classification. 12 Data extraction and analysis from the clinical database was approved by the Research Ethics Committee (11/EM/0190).
Data are presented as means (standard deviation) or medians (interquartile range). Comparisons were undertaken using χ 2 test, Fisher exact test, independent samples t test, or Kruskal-Wallis test, as appropriate. As differences in the distribution of baseline prognostic variables in a nonrandomized comparison may lead to bias, conditional logistic regression with forward selection was used to assess the independent association between thrombolysis and outcomes of mRS 0 to 2 at 90 days, mortality, and symptomatic intracerebral hemorrhage (sICH), adjusting for baseline covariates of age, sex, vascular risk factors and baseline NIHSS score, Alberta Stroke Program Early Computed Tomography Score, blood pressure, and blood glucose. The model fit was assessed using the Hosmer-Lemeshow test, and models with P>0.05 were discarded. The distribution of mRS categories between treated and nontreated WUIS patients was compared using ordinal regression shift analysis adjusted by age and baseline NIHSS score. Two-sided probability values <0.05 were considered significant. IBM-SPSS version 20.0 was used for analyses.
Results
Of the 1 836 ischemic stroke patients admitted during the study period, 193 (10.5%) had wake-up stroke. Of these, 71 were excluded because (1) last seen normal to presentation exceeded 12 hours (n=36); (2) baseline NIHSS<5 (n=12); (3) last seen normal to presentation <4.5 hours or mild deficits with new symptoms after awakening (n=23). Of the remaining 122 WUIS patients, thrombolysis was undertaken in 68 (56%) patients. Fifty-four (44%) patients were not thrombolysed, being unable to give consent and unaccompanied by relative (n=26), refused to consent (n=9), or treating physician decided against thrombolysis based on no or matched deficits on CTP (n=19). Table 1 describes the baseline clinical and imaging data for WUIS patients. The thrombolysed group had more women, higher frequency, and higher baseline NIHSS scores. CTP use was more common in thrombolysed patients, 40% of whom showed a perfusion mismatch. Thrombolysed patients were more likely to have atherosclerotic and cardioembolic strokes, and fewer lacunar strokes. Higher proportions of thrombolysed patients survived and showed better functional outcomes Table 2 ). Any ICH occurred in 12 (22%) of thrombolysed patients of which 2 (3%) were symptomatic. Thrombolysis was associated with a nonsignificant shift toward a better mRS category at 90 days on ordinal regression shift analysis (Figure 1) . Age, baseline NIHSS, and thrombolysis were independent predictors of mortality and good outcome (mRS 0-2) at 90 days (Table 3 ). There were no independent predictors of sICH. Thrombolysis was associated with a 5-fold increase in the odds of a good outcome (mRS 0-2) adjusted for age, sex, and baseline stroke severity.
CTP imaging may have introduced bias favoring better outcomes to the thrombolysis group. CTP imaging was not performed if consent to treatment was not available and 19/46 (41%) patients with CTP imaging who showed no or matched perfusion deficits were not thrombolysed. To exclude this bias, data were reanalysed for patients in whom NCCT was the only imaging modality ( Table 4 ). The baseline NIHSS score was higher in thrombolysed patients (12 versus 9), but they showed a trend toward lower mortality and better functional outcomes at 3 months. Baseline NIHSS score was an independent predictor of good outcome at 90 days (odds ratio 0.47, 95% confidence interval [CI], 0.26-0.86 per point; P=0.014). Thrombolysis was associated with odds ratio 6.5 (95% confidence interval, 1.4-24.7; P=0.03) for mRS 0 to 2 at 90 days, after adjusting for differences in baseline NIHSS score.
Discussion
Many WUIS patients are not eligible for thrombolytic treatment in routine clinical practice because the time of onset is not known. Although this observational study did not show a difference in the primary end point of mRS 0 to 2 at 90 days between thrombolysed and nonthrombolysed WUIS patients (37% versus 26%; P=0.35), thrombolysis was an independent determinant of a better outcome and associated with a 5-fold odds of achieving an mRS 0 to 2 at 90 days without increasing the risk of hemorrhage, after adjusting for differences in baseline NIHSS score. This suggests that thrombolytic treatment in selected WUIS patients is feasible with the potential of benefit over harm.
The outcome of stroke during sleep may be worse compared with patients with known time of stroke onset, 3, 4 and there is increasing awareness that selected WUIS patients may be a reasonable target for intervention. 1 Several studies have shown that WUIS patients have structural and perfusion CT appearances, diffusion, and perfusion weighted magnetic resonance (MR) changes, and intracranial large-vessel occlusions similar to thrombolysed patients with known time of stroke onset. 1, 2, [5] [6] [7] The effect of recanalization interventions in WUIS patients is less clear. In a thrombolysis trial using abciximab, 3/21 (14%) treated WUIS patients had sICH compared with 1/20 patients receiving placebo, resulting in early cessation of the study. 13 An observational study comparing 46 WUIS patients (NIHSS score 16) treated with intravenous or intraarterial rtPA with 34 nontreated WUIS patients (NIHSS score 10.5) showed that thrombolysed WUIS patients had higher adjusted rates of good outcomes (odds ratio, 9.2; 95% confidence interval, 1.9-45; P=0.006).
14 However, only 28 WUIS patients were treated with intravenous rtPA and outcomes were measured Figure. at discharge rather than at 90 days. More recently, a pilot randomized controlled study using CT perfusion mismatch as a selection criterion in 12 WUIS patients showed that 4/6 of thrombolysed patients had reperfused with mRS of 0 to 2 at 90 days compared with only 1/5 in the control group. 15 This study has systematically assessed outcomes at 90 days with and without thrombolysis in consecutive WUIS patients who would have been eligible for treatment on clinical and imaging criteria, if the time of onset was known. The frequency of sICH (2.9%) in this study compared favorably with the 7.1% in WUS patients treated with intravenous rtPA in a previous study 14 and is within the range reported in large registries. 16 The proportion of thrombolysed WUIS patients with an excellent or good outcome (16% and 37%, respectively) and mortality (15%) at 90 days were similar to that reported at discharge from hospital previously. 14 It is possible that use of multimodal CT or MR imaging of the penumbra may help to select WUIS patients most likely to benefit by thrombolytic treatments and increase the percentage of patients with good outcomes. The role of diffusion/perfusion MR or CT mismatch in patient selection remains equivocal 17, 18 and is being investigated in ongoing studies. Newer techniques based on MR assessments of lesion age appear promising, 19 but need confirmation. The study is limited by a relatively small sample size and milder strokes in nonthrombolysed patients, which may be the reason why many percentage differences in outcome did not achieve significance. These outcome differences were all consistent in favoring thrombolysis and the association between good outcomes and thrombolysis were confirmed in analyses adjusted for differences in baseline NIHSS scores. Potential bias in sampling was reduced by consecutive sampling of an ongoing registry using predefined inclusion criteria. Bias because of inaccurate or incomplete data were minimized by using standardized definitions, validated scales, and verification against source data. Outcome assessments were performed by trained and certified observers, who were not involved in patient care. Analyses were prespecified and regression models were used to adjust for potential differences in baseline covariates, when assessing outcome. An inadvertent bias favoring treatment may have resulted from patients with less recovery potential not consenting for a high-risk unproven treatment, but only 9 patients refused consent in this study. CTP imaging is another potential source of bias; however, analyses excluding patients undergoing CTP imaging showed a significant independent relationship between thrombolysis and good outcome at 90 days. Finally, the findings reflect practice and outcome at a single center. Although baseline data did not show any statistical difference between the groups, the proportions of some characteristics were not equally distributed and unmeasured bedside bias because of clinical judgment in case selection for thrombolysis remains unknown.
In conclusion, this single-center preliminary study suggests that thrombolysis in WUIS patients selected on defined clinical and imaging criteria is feasible and may be associated with better outcomes. However, the limitations of design emphasize the need for large, multicenter, intervention studies under controlled conditions in these patients.
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